OICHARTS
8 AMThe 8 AM report →

DTIL

Precision BioSciences, Inc. Common Stock · XNAS · 131 sessions on record
$6.26▲ +0.08 · +1.3%from $6.18 the session before · Sep 30, 2026 close · end of day
Open
$6.24
High
$6.40
Low
$6.14
Day's range
$0.264.2% of the previous close
VWAP
$6.29close −0.44% from it
Volume, shares
249K0.98× the 20-session average
Traded, $
$1.6M
Trades
5.99K42 shares per trade
Previous close
$6.18+0.08 to the close
Market cap
$172.8Mat the close of Sep 30
Day range46% of the way up
$6.14$6.40
52-week range21% of the way up
$5.35 Mar 31$9.62 Jul 7

−35% from the high · +17% from the low

Options

No listed options on DTIL

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
DTIL close over the last 126 sessions, with S&P 500 rebased to the first close4.616.959.28axis spans 101%S&P 500DTILApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 101 percent.

Quarterly results

consolidated · latest filed Aug 6, 2026 · SEC filings

Revenue $0, −100% on a year earlier; profit −$32.7M in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of DTIL on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Aug 6$0▼ −100%−$32.7M—-1.26▲ +0.9%S&P 500 +0.6% · +0.3 pp
Mar 2026filed Aug 6$10.8M▲ +37,000%−$18.4M—-0.75▲ +0.9%S&P 500 +0.6% · +0.3 pp
Dec 2025filed Mar 12$34.2M▲ +5,300%$20.1M—2.62—not reached
Sep 2025filed Nov 3$13.0K▼ −98%−$21.8M—-1.84—not reached
Jun 2025filed Aug 6$18.0K▼ −100%−$23.5M▼ −170%-2.13▲ +0.9%S&P 500 +0.6% · +0.3 pp
Mar 2025filed Aug 6$29.0K▼ −100%−$20.6M▼ −340%-2.21▲ +0.9%S&P 500 +0.6% · +0.3 pp
Dec 2024filed Mar 26$638.0K▼ −91%−$17.7M—-3.08—not reached
Sep 2024filed Nov 3$576.0K▼ −96%−$16.4M—-2.25—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of DTIL on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025$34.3M▼ −50%−$45.7M▼ −740%-3.56
FY24to Dec 2024$68.7M▲ +41%$7.2M—1.04
FY23to Dec 2023$48.7M▲ +94%−$61.3M—-15.96
FY22to Dec 2022$25.1M▼ −78%−$111.6M—-38.10
FY21to Dec 2021$115.5M▲ +380%−$30.6M—-0.52

Fundamentals

consolidated · filings to Jun 2026 · close $6.26 on Sep 30

3.8 times book value, revenue +3,500% over twelve months, market cap $172.8M.

Valuation
Market cap
$172.8Mon Sep 30
Price to earnings
—
Trailing EPS
$-1.23diluted · consolidated · four quarters to Jun 2026
Price to book
3.8consolidated · balance sheet to Jun 2026
Book value a share
$1.64consolidated · balance sheet to Jun 2026
Debt to equity
—
Return on equity
-130%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
3.8market cap over revenue, four quarters to Jun 2026
Shares outstanding
27.6Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
$45.1Mfour quarters to Jun 2026
Revenue growth, 12 months
▲ +3,500%against the twelve months before
Revenue 3-year CAGR
▼ −1.1%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
−$52.7Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—
PeersBiological Products, (No Diagnostic Substances) · the ten largest by market cap · industry P/E needs two stocks with trailing profit and a market cap
Stocks in the industry Biological Products, (No Diagnostic Substances) with market cap, price to earnings and price to book
StockMarket capP/EP/BClose $
MRNAModerna, Inc. Common Stock$76.88Bon Sep 30—11$192.57
HALOHalozyme Therapeutics, Inc.$12.53Bon Sep 3032consolidated87$110.40
TECHBio-Techne Corp.$11.36Bon Sep 3062consolidated5.4$72.47
KODKodiak Sciences Inc Common Stock$5.96Bon Sep 30—98$94.80
ALLOAllogene Therapeutics, Inc. Common Stock$552.8Mon Sep 30—1.3$1.60
DTILPrecision BioSciences, Inc. Common Stock$172.8Mon Sep 30—3.8$6.26
OTLKOutlook Therapeutics, Inc. Common Stock$139.6Mon Sep 30——$0.57
BSEMBioStem Technologies, Inc. Common Stock$55.2Mon Sep 30—2.0$3.09
TVGNTevogen Inc. Common Stock$43.1Mon Sep 30——$6.62
BCDABioCardia, Inc. Common Stock$15.3Mon Sep 30—5.7$1.01

Shareholding

SEC Forms 3, 4 and 5

No open-market insider buying or selling in the last 90 days.

Insider tradesSEC Forms 3, 4 and 5 · the latest 10
DTIL insider trades
InsiderTradeSharesPriceHeld after
Germano Geno JDirectorexercised · May 20, 202621,000—44,883
Pire Shari LisaDirectorexercised · May 20, 202621,000—35,028
Brown MelindaDirectorexercised · May 20, 202621,000—44,346
Frankel StanleyDirectorexercised · May 20, 202621,000—40,478
Buehler KevinDirectorexercised · May 20, 202621,000—49,137
SMITH J. JEFFERSONOfficerexercised · Feb 17, 202616,667$0.00126,851
SMITH J. JEFFERSONOfficersold · Feb 18, 20264,925$3.84121,926
Scimeca DarioOfficerexercised · Feb 17, 202616,667$0.0061,382
Scimeca DarioOfficersold · Feb 18, 20264,925$3.8456,457
Kelly John AlexanderOfficersold · Feb 18, 20268,149$3.84125,883

Corporate actions

exchange records

No corporate action on record for DTIL yet.

Price history

131 sessions on record · to Sep 30 · end of day

DTIL is −18.1% over 20 sessions against the S&P 500's +0.1%, 35% below its 52-week high, realised volatility 62% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $DTIL %S&P 500 %Difference pp
120 sessionssince Apr 9$6.61▼ −5.3%▲ +12%−17
60 sessionssince Jul 7$9.25▼ −32%▲ +2.0%−34
20 sessionssince Sep 1$7.64▼ −18%▲ +0.11%−18
5 sessionssince Sep 23$6.36▼ −1.6%▼ −0.67%−0.90
1 sessionsince Sep 29$6.18▲ +1.3%▼ −0.21%+1.5
Averages of the closeclose against each average
5-session average
$6.25close +0.16% from it
20-session average
$6.80close −7.9% from it
50-session average
$7.32close −14% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$0.416.6% of the close
Average day's range, 20
$0.355.6% of the close
Volume against 20 sessions
0.98×249K vs 258K average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
62%≈ ±3.9% a session · moved more than that on 3 of 20
Realised volatility, 60
56%≈ ±3.5% a session · moved more than that on 14 of 60
Beta to S&P 500, 60
0.97moved with S&P 500 on 30 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
6 up · 13 downof 19
Last 60 sessions
22 up · 36 downof 58
Best session, 250
▲ +12%Jul 7
Worst session, 250
▼ −12%Sep 23

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 55% of reported volume on Sep 30, 2026, against 59% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
DTIL daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 202631.5K57.7K54.6%
Sep 29, 202621.4K35.1K60.9%
Sep 28, 202668.3K86.9K78.6%
Sep 25, 202658.2K68.4K85.1%
Sep 24, 202697.6K124K79.0%
Sep 23, 202667.3K128K52.6%
Sep 22, 202654.5K152K35.8%
Sep 21, 202658.4K98.8K59.1%
Sep 18, 202624.4K32.7K74.8%
Sep 17, 202682.8K155K53.5%

Filings

SEC EDGAR · newest first
DTIL SEC filings
FiledFormReport date
Sep 30, 20264Sep 28, 2026
Sep 29, 20264Sep 25, 2026
Sep 29, 20264Sep 25, 2026
Aug 24, 2026SCHEDULE 13G/A—
Aug 24, 20268-KAug 24, 2026
Aug 7, 2026S-8—
Aug 6, 202610-QJun 30, 2026
Aug 6, 20268-KAug 6, 2026
Aug 3, 20263Aug 1, 2026
Aug 3, 20263Aug 1, 2026
Aug 3, 20263Aug 1, 2026
Jul 29, 2026SCHEDULE 13G/A—
Jul 27, 20268-KJul 23, 2026
Jul 20, 2026SCHEDULE 13G—
Jul 1, 20268-KJul 1, 2026
Jun 16, 20268-KJun 10, 2026
Jun 5, 20264Jun 3, 2026
Jun 5, 20264Jun 3, 2026
Jun 5, 20264Jun 3, 2026
Jun 5, 20264Jun 3, 2026
Jun 5, 20264Jun 3, 2026
Jun 3, 20264Jun 1, 2026
Jun 3, 20264Jun 1, 2026
Jun 3, 20264Jun 1, 2026
Jun 3, 20264Jun 1, 2026

About Precision BioSciences, Inc. Common Stock

SEC and exchange records
Company
Precision BioSciences, Inc. Common Stock
Exchange
XNAS
Industry
Biological Products, (No Diagnostic Substances) · SEC standard industrial classification
SEC CIK
1357874
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 10:42 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.